Alteri Wealth LLC Makes New $546,000 Investment in Pfizer Inc. (NYSE:PFE)

Alteri Wealth LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,593 shares of the biopharmaceutical company's stock, valued at approximately $546,000.

Several other institutional investors also recently modified their holdings of the stock. American Trust Investment Advisors LLC increased its holdings in Pfizer by 16.0% in the 4th quarter. American Trust Investment Advisors LLC now owns 38,499 shares of the biopharmaceutical company's stock worth $1,021,000 after purchasing an additional 5,305 shares in the last quarter. Aptus Capital Advisors LLC increased its stake in shares of Pfizer by 124.0% in the fourth quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company's stock valued at $5,922,000 after buying an additional 123,543 shares during the period. Anson Funds Management LP raised its holdings in Pfizer by 20.0% in the 4th quarter. Anson Funds Management LP now owns 120,000 shares of the biopharmaceutical company's stock valued at $3,184,000 after buying an additional 20,000 shares during the last quarter. Aspire Growth Partners LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $592,000. Finally, Ategra Capital Management LLC bought a new stake in Pfizer during the 4th quarter worth approximately $1,326,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Performance

PFE stock traded down $0.34 during midday trading on Monday, hitting $23.86. The company's stock had a trading volume of 40,532,428 shares, compared to its average volume of 40,491,431. The stock has a market cap of $135.32 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average price is $24.34 and its 200 day moving average price is $25.73. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. The company's quarterly revenue was down 7.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.21%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.